LEO Pharma
As of the edition of 20 October 2026, LEO Pharma runs 42 drugs, 21 of them marketed; it is on route A at 0 targets and on route B at 9 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 21 |
| Active | 3 |
| Went quiet | 10 |
| Stopped | 5 |
| Status not established | 3 |
| Total | 42 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tacrolimus anhydrous | Ends 2028 (exclusivity) | 3 |
| Hydrocortisone | none listed | 5 |
| Heparin | none listed | 5 |
| Calcipotriene | none listed | 1 |
| Betamethasone | none listed | 6 |
| Ingenol mebutate | none listed | 1 |
| Brodalumab | Ends 2029 (computed from the first US licence) | 3 |
| Betamethasone dipropionate | none listed | 3 |
| Tralokinumab | Ends 2033 (computed from the first US licence) | 1 |
| Spesolimab | Ends 2034 (computed from the first US licence) | 0 |
| Tinzaparin | none listed | 0 |
| Azelaic acid | none listed | 0 |
| Delgocitinib | Ends 2031 (patent) | 4 |
| Heparin sodium | none listed | 3 |
| Tinzaparin sodium | none listed | 0 |
| Fusidic acid | none listed | 0 |
| Betamethasone valerate | none listed | 4 |
| Hydrocortisone acetate | none listed | 2 |
| Desonide | none listed | 3 |
| Methylprednisolone aceponate | none listed | 0 |
| Diflucortolone | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 9 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where LEO Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Skin and connective tissue: 72 trials led
- Cancer: 27 trials led
- Inherited and neonatal: 27 trials led